Unlike SOLO-1 or PAOLA-1, PRIMA included both HRD-positive and HRD-negative patients — and many in the control arm later received PARP inhibitors (~40–50%). Result: PFS & QoL benefits persist, but no OS separation. The message? 🔬 HRD testing still matters. #Oncology #PARP

Quitting smoking after a cancer diagnosis isn’t “too late.” Even in stage III–IV, stopping within 6 months boosts 2-year survival from 74.7% → 85.1%. That’s nearly double the mortality risk if you keep smoking (aHR 1.97). Smoking cessation should be the 4th pillar of cancer

Precision surgery in cervical cancer, backed by evidence. The PHENIX trial (NEJM 2025) shows that Sentinel lymph-node biopsy (SLNB-only) is non-inferior to pelvic lymphadenectomy for 3-year DFS — while reducing lymphedema, lymphocele, and pain by 3–4×. Minimal harm, maximal

Actionable genetic alterations now define modern oncology. From tumor-specific targets like ALK, EGFR, KRAS to tumor-agnostic biomarkers such as MSI-H, NTRK, RET, HER2 IHC3+, and BRAF V600E — this is precision medicine, 2025 edition. 🧬✨ #Oncology #PrecisionMedicine #FDA

MATTERHORN #ESMO25 – LBA81 Durvalumab + FLOT becomes the first peri-operative immunotherapy regimen to show an overall survival benefit in resectable gastric/GEJ cancer. Viewed alongside the #ASCO25 interim (EFS, pCR) results, the final OS data complete the picture —

Adjuvant ribociclib extends protection well beyond treatment. At #ESMO25 (LBA14), 5-year NATALEE data show: 🟦 iDFS 85.5% vs 81.0% (HR 0.716) 🟩 DDFS HR 0.709 🟧 Emerging OS trend (HR 0.80) 3 years of ribociclib → 5 years of impact in early HR+/HER2– breast cancer.

Combining precision with consolidation. At #ESMO25 (LBA72), the NorthStar trial shows that adding local consolidative therapy (LCT) to osimertinib extends PFS by 34% in EGFR-mutant NSCLC (25.3 vs 17.5 mo, HR 0.66, p=0.025). A chemo-free, tolerable path for oligometastatic

“Less can truly be more.” At #ESMO25, both ARASAFE and DISCUS trials highlight that treatment optimisation in GU oncology can maintain efficacy while reducing toxicity and improving patient access. Thoughtful design, real-world impact. Congratulations to Yüksel Ürün for an

Presented by Xiuning Le MD PhD at #ESMO25 and published simultaneously in NEJM (SOHO-01) Sevabertinib is a selective, EGFR-WT–sparing HER2 TKI combining strong efficacy with clean tolerability. Phase III SOHO-02 now enrolling. #ESMO25 #LCSM ESMO - Eur. Oncology OncLive.com 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Tuğba Başoğlu, MD

VIKTORIA-1 (LBA17, #ESMO25): After CDK4/6i, adding gedatolisib (dual PI3K/mTORi) to fulvestrant ± palbociclib achieved remarkable PFS gains in HR+/HER2–, PIK3CA-WT ABC. Dual PI3K/mTOR blockade may redefine 2L therapy after CDK4/6i. #BreastCancer #Oncology OncLive.com 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏

From routine imaging to predictive insight! At #ESMO25 (Abstract 1080), a deep-learning analysis reveals that thymic health on standard CT scans can forecast immunotherapy response across cancers. Higher thymic health = ↓ risk of progression (HR 0.65) & ↓ mortality (HR 0.56),

Two paths emerging for ES-SCLC maintenance after chemo-immunotherapy. The DeLLphi-303 study explores DLL3-directed T-cell engagement (tarlatamab + PD-L1), while a phase II trial tests ATR inhibition (ceralasertib + durvalumab) to enhance immune persistence. #ESMO25 #SCLC

The most decisive step on the road to cure in muscle-invasive bladder cancer was met with a standing ovation at #ESMO25 👏👏 A historic moment for uro-oncology. #BladderCancer #Oncology #Immunotherapy #ADC ESMO - Eur. Oncology OncLive.com 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Tuğba Başoğlu, MD Elvina Almuradova Atakan Demir MD

For the first time, a significant overall survival benefit with immunotherapy in platinum-resistant ovarian cancer! #ESMO25 #Immunotherapy #GynOnc #KeynoteB96 #Oncology ESMO - Eur. Oncology OncLive.com 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 Tuğba Başoğlu, MD Elvina Almuradova Atakan Demir MD Mükremin Uysal, MD Yakup Ergün OncoAlert

Dual-Target Breakthrough in Lung Cancer At #ESMO25, the Phase 3 HARMONi-6 trial showed that ivonescimab (PD-1 × VEGF) + chemotherapy significantly improved PFS compared with PD-1 + chemo. Although OS data are still immature, the striking PFS advantage signals that this

Sac-TMT ushers in the ADC era for EGFR-mutant lung cancer. In the phase 3 OptiTROP-Lung04 trial, TROP2-targeting ADC monotherapy doubled PFS and cut mortality risk by 40% #ESMO25 #NSCLC #EGFR #TROP2 #ADC #Oncology #LungCancer #PrecisionMedicine #ImmunoOncology #ClinicalTrials

Not all PSMA-positive patients are the same.; In PSMAddition, adding Lu-177 to ADT + ARPI modestly delayed progression but didn’t improve OS — and patient-reported QoL was slightly worse. Upfront use remains experimental until mature survival and biomarker-based subgroup data

Breaking the Wall of the Undruggable For decades, KRAS has been the emblem of “the undruggable.” Now, selective G12D inhibitors are showing clinical traction — delivering meaningful responses and molecular remissions, particularly in pancreatic adenocarcinoma. #ESMO25